FDA Brief

Warning letters Food

FDA warning letter to

Dr. Garber’s Natural Solutions

LowIssued Feb 18, 2021Posted Feb 19, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA warned Dr. Garber's Natural Solutions that website claims make Depression Relief an unapproved new drug and misbranded.

What happened

FDA reviewed www.drgarbers.com in January and February 2021 and found the site takes orders for Dr. Garber's Depression Relief. FDA found website claims, including relief of temporary depression or occasional sadness and a video titled "Dealing with post partum depression. naturally," that show the product is intended to treat disease.

What FDA found

  1. The website claims show Dr. Garber's Depression Relief is intended to relieve depression and postpartum depression, so FDA treats it as a drug under federal law.

    section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. The product is a new drug because FDA says it is not generally recognized as safe and effective for these uses and has no FDA approval.

    section 201(p), sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 321(p), 331(d), 355(a)]
  3. The product is misbranded because it lacks adequate directions for a layperson to use it safely for a condition that needs a licensed practitioner's supervision.

    section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 CFR § 201.5
  4. Offering this misbranded drug for interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA tells the company to take prompt action to address the violations and to notify FDA in writing within 15 working days of the steps taken, with documentation and a plan to prevent recurrence. If the company believes there is no violation, it must explain why with supporting information.

Who should pay attention

  • marketers of supplements with disease-treatment claims
  • retailers and online platforms selling Depression Relief
  • companies making mental health-related products with drug-like claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk